Filter Search


Healthcare and Medical


Location Summary Deadline
Germany Open House Pharmaceutical Dact Treaties Formoterol, Glycopyrronium Bromide And Budesonide, Atc R03al11 2025-11-18
Germany Completion Of A Non -excessive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Goliumumab, Atc L04ab06 For The Time 01.07.2025 30.06.2027 2025-11-18
Germany Open House Pharmaceutical Department Treaties Iron (iii) Derisomaltosis, Atc B03ac08 2025-11-18
Germany Open House Pharmaceutical Discount Contracts In Accordance With Section 130a Par. 8c Sgb V Eribulin, Atc L01xx41 2025-11-18
Germany Completion Of A Non -excessive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Lamivudin + Dolutegravir, Atc J05ar25 For The Time 01.07.2025 30.2027 2025-11-18
Germany Completion Of A Non -excessive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Epinephrin, Atc C01ca24 For The Time 01.07.2025 30.06.2027 (plus Extension Option 1x12 Months) 2025-11-18
Germany Completion Of A Non -excessive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Lapatinib, Atc L01eh01 For The Time 01.07.2025 30.06.2027 (plus Extension Option 1x 12 Months) 2025-11-18
Germany Completion Of A Non -excessive Discount Agreement According To § 130a Para. 8 Sgb V To The Active Ingredient Saproptera (exclusively Dosage Form Ple), Atc A16ax07 For The Time 01.07.2025 30.2027 2025-11-18
Germany Completion Of Non -existing Discount Agreements According To § 130 A Para. 8 Sgb V With The Active Ingredient Epoetin Zeta 2025-11-18
Canada Participant Of Cybera Shareit Buying Group 2025-11-18
Whats app